Cargando…
The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
INTRODUCTION: The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to facilitate insulin secretion by reducing glucagon and inhibiting glucagon like peptides. With a vague consensus, the adv...
Autores principales: | Tang, Qizhi, Pan, Weiyu, Peng, Liangyue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437312/ https://www.ncbi.nlm.nih.gov/pubmed/36060938 http://dx.doi.org/10.3389/fendo.2022.962385 |
Ejemplares similares
-
Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2020) -
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
por: Tang, Qizhi, et al.
Publicado: (2022) -
Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study
por: Cercato, Cintia, et al.
Publicado: (2019) -
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021) -
Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: Systematic review and meta-analysis
por: Juan, Juan, et al.
Publicado: (2022)